Isomorphic Labs, the AI drug discovery startup founded by Demis Hassabis, raised $2.1 billion in a Series B funding round this month, led by Thrive Capital, according to fortune.com. The capital injection aims to accelerate the company’s next phase of growth by scaling computing power, generating more data, and expanding its drug discovery programs.
The funding round reflects Isomorphic’s strategic focus on increasing computational resources to enhance the speed and scale of experiments and inferences in drug development. Hassabis highlighted that while the compute needs differ from those of an artificial general intelligence lab, more computing capacity allows for more extensive experimentation. The company is also exploring the development of automated laboratories, though Hassabis noted that further research is needed to perfect automation before full implementation.
This funding milestone underscores the growing importance of AI-driven approaches in pharmaceutical research, where computational power and data generation are critical to accelerating drug discovery. The $2.1 billion raise positions Isomorphic Labs among the top-funded startups in this sector, reflecting investor confidence in AI’s potential to reduce friction in the traditionally slow and costly drug development process.
Looking ahead, Isomorphic plans to use the new capital to turbocharge its infrastructure and research capabilities. The company aims to expand its computational experiments and data generation efforts while continuing to explore automation technologies for lab work. Observers will watch how Isomorphic balances scaling compute with advancing automation to maintain its competitive edge in AI-powered drug discovery.